<DOC>
	<DOCNO>NCT01127074</DOCNO>
	<brief_summary>In last year great attempt develop active immunotherapy breast cancer patient ( BCPs ) use undefined well select antigen activate tumor specific T-lymphocytes . The purpose phase-I study determine safety feasibility vaccination allogeneic breast cancer cell line , KS24.22 , genetically modify express CD80 Her-2/neu , evaluate efficacy induce tumor antigen-specific immune response human leukocyte antigen ( HLA ) -A*02-matched patient metastatic breast cancer .</brief_summary>
	<brief_title>Vaccination Metastatic Breast Cancer Patients With CD80-modified Allogeneic Cancer Cell Line ( KS2422 )</brief_title>
	<detailed_description>The trial design open label phase-I . Informed consent give twice patient ( 1st HLA-typing , 2nd participation vaccination trial ) . The first four vaccination , give every two week , follow four monthly vaccination . Additional vaccination permit request patient exhibit stable disease ( SD ) . Immediately administration , KS24.22 cell thaw lethally irradiate . KS24.22 cell adjust 10E7/ml Ringer-Lactate-solution , transfer 1 ml syrinx store ice inject within time frame 2h . Vaccinations give i.d . thigh total volume 1 ml divide two injection site .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>proven diagnosis carcinoma breast distant metastatic disease patient receive either anthracycline taxanebased chemotherapy ( `` state art '' ) Karnofsky Score ( performance status ) 80 % HLA*A0201positive minimum life expectancy 6 month write informed consent activation patient 's Tlymphocytes mitogen antibody cell line use vaccination manifestation CNS metastases immunosuppressive disease like AIDS , autoimmune disease serious concomitant systemic medical disorder active acute systemic infection pregnancy chemotherapy radiotherapies 4 week precede study entry biological response modifier ( antibody , TNF , cytokine ) immune therapy 6 week precede study entry ( exclusion : hematopoetic growth factor ) organ transplant patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>breast cancer stage IV</keyword>
	<keyword>vaccination</keyword>
	<keyword>CD80</keyword>
	<keyword>immunotherapy</keyword>
</DOC>